A (t)
It is not easy to
give an answer about acyclovir security and more precisely
during a long term use (see our article C.9. Acyclovir (Zovirax®) : un
traitement dangereux de l'herpès pour les personnes
séropositives mais aussi pour les personnes non
séropositives ?).
As HHV8 would favour
Kaposi's sarcoma appearance for HIV+ persons, studies have
been carried out to determine whether drugs acting against
other human herpes viruses (HHV 1 and 2) could treat
Kaposi's sarcoma. No effect has been observed with
ganciclovir and foscarnet. On the contrary with acyclovir,
an unexpected increase of the frequency of Kaposi's sarcoma
has been mentionned in some studies.
Concerning multiple
sclerosis, HHV6 would favour its outbreak (may be HHV6-B,
according to Nature Medicine article). We don't know any
study concerning acyclovir use in multiple sclerosis
treatment.
Among HHV6 viruses, HHV6-A
(the variant A strain of HHV6) would intervene during HIV
infection. HHV6-A would act by impairing antigen
presentation (of some particular proteins of HIV in case of
HIV infection) from macrophages-monocytes to CD4 cells,
leading to perturbation in antibodies production (TH2 CD4
sub-type responde) and CD8 cytotoxic lymphocytes (CTLs)
intervention to kill infected cells (TH1 CD4 sub-type
response).
In addition, HIV tat gene
enhances HHV6-A replication.
To act against HHV6-A,
some, like Keep Hope Alive (PO Box 27041 West Allis, WI
53227; Internet: http://www.execpc.com/~keephope/keephope.html) propose lauric acid from coconut
oil use (24 gramme/day) and/or Monolaurin.
To have more precisions
concerning HHV6 virus, we advise you to contact Keep Hope
Alive. (9711)
